Growth hormone-releasing hormone (GHRH) analog peptide
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog developed by ConjuChem with drug affinity complex (DAC) technology for extended half-life. It is not FDA-approved for any indication; ConjuChem discontinued clinical development. It is widely used in research-chemical and telehealth contexts, frequently stacked with ipamorelin.
Track claims and development history. Do not publish dosing, sourcing, or treatment instructions. Separate the single published pharmacokinetic study from community dosing protocols.
A published pharmacokinetic/pharmacodynamic study (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism) showed that CJC-1295 increased GH and IGF-1 levels in healthy subjects for up to 6 days after a single dose — this is the primary peer-reviewed human data.
CJC-1295 was developed by ConjuChem Biotechnologies using drug affinity complex (DAC) technology to bind albumin and extend half-life from minutes to days; clinical development was discontinued and the compound was never submitted to FDA for approval.
Two forms exist in community discussions: CJC-1295 with DAC (extended half-life) and CJC-1295 without DAC (modification GRF 1-29); both are research-use-only and not FDA-approved.
Commonly stacked with ipamorelin (a GHS) in online protocols based on the theoretical rationale of combining GHRH and GHS pathways; this combination has no FDA-approved clinical data.
Evidence level: Peer reviewed
Sources: Journal of Clinical Endocrinology & Metabolism (PubMed)
Cite the Teichman et al. (2006) JCEM publication directly. The study was a single-dose pharmacokinetic study in healthy volunteers, not a clinical outcomes trial. Do not extrapolate to efficacy claims.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration, U.S. Food and Drug Administration
ConjuChem discontinued development; no FDA approval record exists. Products sold as 'research use only' are subject to FDA enforcement.
Evidence level: Community discussion
Sources: U.S. Food and Drug Administration
This combination is based on theoretical synergy between GHRH and GHS pathways but lacks clinical trial data for the combination. Track as a community protocol pattern.
Source records are stored in the repo and linked from each claim.
Teichman et al. (2006) pharmacokinetic study (PMID 16569233) showing that CJC-1295 increased GH and IGF-1 levels in healthy subjects for up to 6 days after a single dose. The primary published human data for CJC-1295.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that stimulates GH release via ghrelin receptor...
Evidence reviewMK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue developed by Merck that mimics ghrelin t...
Evidence reviewSermorelin is a synthetic N-terminal fragment (1-29) of growth hormone-releasing hormone (GHRH) that was formerly FDA-ap...
Evidence reviewTesamorelin (brand name Egrifta) is an FDA-approved growth hormone-releasing hormone (GHRH) analog indicated for the red...
Regulatory watch